The Claim
In patients with type 2 diabetes and HbA1c levels below 7%, those with a red blood cell lifespan shorter than 90 days have a higher median hemoglobin glycation index (HGI) of 0.58% (IQR: 0.18–1.11) compared to 0.25% (IQR: −0.09–0.55) in those with RBC lifespan of 90 days or more, indicating that HbA1c underestimates average blood glucose levels more significantly in individuals with shorter red blood cell lifespans.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If someone with type 2 diabetes has red blood cells that don’t live as long, their A1c test might be giving a lower number than their real blood sugar levels — meaning the test could be misleading for them.
See the scientific wording
In type 2 diabetes patients with HbA1c <7%, the median hemoglobin glycation index (HGI) is 0.58% (IQR: 0.18–1.11) in those with red blood cell lifespan <90 days, compared to 0.25% (IQR: −0.09–0.55) in those with RBC lifespan ≥90 days, indicating greater underestimation of glycemia by HbA1c in the short-lifespan group.
What the research says
1 studyPeople with shorter-lived red blood cells have a bigger gap between their HbA1c test and their actual blood sugar levels, which this study confirms.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.